Currently, GLP-1-based therapies, such as GLP-1 receptor agonists (GLP-1RAs) including exendin-4 and liraglutide, are used for the treatment of type 2 diabetes (T2DM) and act similarly to GLP-1 [7]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.